Abstract 14848: Meta-analysis of the Effects of Carvedilol vs Metoprolol on All-cause Mortality and Hospitalizations in Patients With Heart Failure
Introduction:Long-term treatment with appropriate doses of carvedilol or metoprolol is currently recommended for patients with Heart Failure with reduced Ejection Fraction (HFrEF) to decrease the risk of death, hospitalizations and patients’ symptoms. It remains unclear if the b-blockers used in HFrEF patients are equal or carvedilol is superior to metoprolol types.
Methods: We performed a meta-analysis of the comparative effects of carvedilol vs metoprolol tartrate and succinate on all-cause mortality or/and hospitalization. We conducted an EMBASE and MEDLINE search for prospective controlled trials and cohort studies of patients with HFrEF who were received to treatment with carvedilol vs. metoprolol.
Results: We identified 4 prospective controlled and 6 cohort studies with 30943 that received carvedilol and 69925 patients on metoprolol types (tartrate and succinate) with an average follow up duration of 36.4 months. All-cause mortality was reduced in prospective studies with carvdedilol vs metoprolol tartrate. Neither all-cause mortality nor hospitalizations were significantly different between carvedilol and metoprolol succinate in the cohort studies.
Conclusion: In patients with HFrEF carvedilol and metoprolol succinate have similar effectiveness in reducing all-cause mortality.
Author Disclosures: A. Briasoulis: None. S. Mallikethi-Reddy: None. S. Sharma: None. R. Sudhakar: None. L. Afonso: None.
- © 2015 by American Heart Association, Inc.